

Zejula[®] (niraparib) – Indication update

- On November 11, 2022, <u>GSK announced</u> an update that at the request of the FDA, it will restrict the second-line maintenance indication for <u>Zejula (niraparib)</u> to only the patient population with deleterious or suspected deleterious germline BRCA mutations (gBRCAmut).
- The US first-line indication of Zejula remains unchanged for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy.
- This decision follows an FDA review of the final overall survival (OS) analysis of the ENGOT-OV16/NOVA Phase 3 trial, which served as the basis for the approval of the second-line maintenance indication.
 - In the final OS results, the secondary endpoint of OS demonstrated a hazard ratio (HR) of 1.06 (95% CI: 0.81, 1.37) in the non-gBRCAmut cohort.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.